A randomized, placebo-controlled study of VASCAZEN in omega-3 fatty acid deficient patients with cardiovascular disease risk factors

Trial Profile

A randomized, placebo-controlled study of VASCAZEN in omega-3 fatty acid deficient patients with cardiovascular disease risk factors

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Eicosapentaenoic acid/docosahexaenoic acid (Primary)
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Acronyms VASCAZEN-REVEAL
  • Sponsors Pivotal Therapeutics
  • Most Recent Events

    • 03 May 2013 Top-line results presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, according to a Pivotal Therapeutics media release.
    • 09 Apr 2013 Top-line results will be presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, according to a Pivotal Therapeutics media release.
    • 09 Apr 2013 Primary endpoint `correction of omege-3 deficiency' has been met, according to a Pivotal Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top